People · Operator
Named in public records as an officer, director or promoter · active 2013–2017 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Avitide, Inc. | — | Pharmaceuticals | Series A | $40.9M | $309.7M | 2013 |
Warren Kett at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Warren Kett on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michael Ross | 1 | 18 |
| Ajay Royan | 1 | 13 |
| Rishi Gupta | 1 | 12 |
| Errik Anderson | 1 | 8 |
| Ian Ratcliffe | 1 | 6 |
| Philip Ferneau | 1 | 6 |
| Claudio Nessi | 1 | 5 |
| Tillman Gerngross | 1 | 5 |
| Colin Greenspon | 1 | 3 |
| Jonathan Sheller | 1 | 2 |
| Scott Kennedy | 1 | 2 |
| Kevin Issett | 1 | 1 |
| Kevin Isett | 1 | 1 |
| Jon Sheller | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.